Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,133,220
  • Shares Outstanding, K 34,340
  • Annual Sales, $ 327,870 K
  • Annual Income, $ -13,920 K
  • 36-Month Beta 0.78
  • Price/Sales 3.45
  • Price/Cash Flow 0.00
  • Price/Book 6.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.54 +3.27%
on 07/10/17
33.95 -4.06%
on 07/19/17
+0.70 (+2.20%)
since 06/27/17
3-Month
28.64 +13.73%
on 05/25/17
33.97 -4.11%
on 06/22/17
-0.21 (-0.63%)
since 04/27/17
52-Week
25.66 +26.94%
on 08/26/16
33.97 -4.11%
on 06/22/17
+3.98 (+13.93%)
since 07/27/16

Most Recent Stories

More News
Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2017 financial...

GHDX : 32.54 (-1.39%)
Global Market for Laboratory-Developed Testing - Expected to Increase from Nearly $11 Billion in 2016 to $14.9 Billion in 2021

Research and Markets has announced the addition of the "Laboratory-developed Testing: Technologies and Markets" report to their offering. The report includes an overview of the global market for laboratory-developed...

ENZ : 11.00 (-2.57%)
MKGAY : 38.3600 (-0.62%)
GHDX : 32.54 (-1.39%)
DGX : 108.47 (+0.23%)
MYGN : 23.38 (-1.52%)
Genomic Health Cancer Tests Strong, Operating Expenses a Woe

On Jun 19, we issued an updated research report on Redwood City, CA-based Genomic Health Inc (GHDX), a global cancer research company with a focus on advanced molecular diagnostics.

GHDX : 32.54 (-1.39%)
AXDX : 26.95 (-2.71%)
ALGN : 157.37 (-0.83%)
INGN : 93.87 (-1.90%)
Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GHDX : 32.54 (-1.39%)
Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types

Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of eight studies that provide additional evidence of the value of Oncotype DX® tests in predicting clinically meaningful endpoints...

GHDX : 32.54 (-1.39%)
Genomic Health to Unveil Oncotype DX Study Results at ASCO

Global cancer research company Genomic Health, Inc. (GHDX) will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago.

GHDX : 32.54 (-1.39%)
AXDX : 26.95 (-2.71%)
LMNX : 20.24 (-1.22%)
INGN : 93.87 (-1.90%)
Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session

Genomic Health (GHDX) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.

GHDX : 32.54 (-1.39%)
VVUS : 1.14 (-4.20%)
SmarTrend Watching for Potential Pullback in Shares of Genomic Health After 2.95% Gain

Genomic Health (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $29.70 to a high of $30.94. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of...

GHDX : 32.54 (-1.39%)
Genomic Health Q1 Results Weak, Cancer Test Business Strong

On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).

HOLX : 44.34 (-1.77%)
EW : 116.71 (+0.95%)
GHDX : 32.54 (-1.39%)
LMNX : 20.24 (-1.22%)
Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive

Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.

HOLX : 44.34 (-1.77%)
GHDX : 32.54 (-1.39%)
LMNX : 20.24 (-1.22%)
SSH : 0.61 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Support & Resistance

2nd Resistance Point 33.72
1st Resistance Point 33.36
Last Price 32.54
1st Support Level 32.76
2nd Support Level 32.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.